Controlled-release basic fibroblast growth factor for peripheral artery disease: Comparison with autologous bone marrow-derived stem cell transfer

Tissue Engineering - Part A

Volumn 17, Issue 21-22, 2011, Pages 2787-2794

  Takagi, Gen ^a   Miyamoto, Masaaki ^a   Tara, Shuhei ^a   Takagi, Ikuyo ^a   Takano, Hitoshi ^a   Yasutake, Masahiro ^a   Tabata, Yasuhiko ^b   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GAS ANALYSIS; BONE; CELL CULTURE; DISEASES; DRUG DELIVERY; FIBROBLASTS; HYDROGELS; NUCLEAR MEDICINE; PEPTIDES; STEM CELLS; TECHNETIUM;

ANKLE-BRACHIAL INDICES; BASIC FIBROBLAST GROWTH FACTOR; BIODEGRADABLE HYDROGELS; BONE MARROW; CONTROLLED RELEASE; DRUG DELIVERY SYSTEM; GELATIN HYDROGELS; MARROW-DERIVED STEM CELLS; MONONUCLEAR CELLS; OXYGEN TENSION; PERIPHERAL ARTERY DISEASE; TRANSCUTANEOUS;

SAFETY FACTOR;

FIBROBLAST GROWTH FACTOR 2;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CLINICAL TRIAL; CYTOLOGY; HUMAN; METHODOLOGY; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; STEM CELL; STEM CELL TRANSPLANTATION;

ADULT; AGED; BONE MARROW CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 80155199659     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2010.0525     Document Type: Article

References (32)

1. Carmeliet, P. Angiogenesis in health and disease. Nat Med 9, 653, 2003.
2. Folkman, J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6, 273, 2007.
3. Moreno, P.R., Sanz, J., and Fuster, V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol 53, 2315, 2009.
4. Alpert, J.S., Larsen, O.A., and Lassen, N.A. Exercise and intermittent claudication. Blood flow in the calf muscle during walking studied by the xenon-133 clearance method. Circulation 39, 353, 1969.
5. Kutryk, M.J., and Stewart, D.J. Angiogenesis of the heart. Microsc Res Tech 60, 138, 2003.
6. Lundgren, F., Dahllof, A.G., Lundholm, K., Schersten, T., and Volkmann, R. Intermittent claudication-surgical reconstruction or physical training?. A prospective randomized trial of treatment efficiency. Ann Surg 209, 346, 1989.
7. Nagy, J.A., Dvorak, A.M., and Dvorak, H.F. VEGF-A(164/ 165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med 13, 169, 2003.
8. Cao, Y., Hong, A., Schulten, H., and Post, M.J. Update on therapeutic neovascularization. Cardiovasc Res 65, 639, 2005.
9. Simons, M., and Ware, J.A. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2, 863, 2003.
10. Kamihata, H., Matsubara, H., Nishiue, T., et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104, 1046, 2001.
11. Uemura, R., Xu, M., Ahmad, N., and Ashraf, M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 98, 1414, 2006.
12. Tateno, K., Minamino, T., Toko, H., et al. Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res 98, 1194, 2006.
13. Tabata, Y., Nagano, A., and Ikada, Y. Biodegradation of hydrogel carrier incorporating fibroblast growth factor. Tissue Eng 5, 127, 1999.
14. Miyamoto, M., Yasutake, M., Takano, H., et al. Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant 13, 429, 2004.
15. Kawanaka, H., Takagi, G., Miyamoto, M., et al. Therapeutic angiogenesis by controlled-release fibroblast growth factor in a patient with Churg-Strauss syndrome complicated by an intractable ischemic leg ulcer. Am J Med Sci 338, 341, 2009.
16. Marui, A., Tabata, Y., Kojima, S., et al. A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. Circ J 71, 1181, 2007.
17. Tabata, Y., and Ikada, Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials 20, 2169, 1999.
18. Simons, M., Annex, B.H., Laham, R.J., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105, 788, 2002.
19. Laham, R.J., Sellke, F.W., Edelman, E.R., et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100, 1865, 1999.
20. Schumacher, B., Pecher, P., von Specht, B.U., and Stegmann, T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97, 645, 1998.
21. Schumacher, B., Stegmann, T., and Pecher, P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg (Torino) 39, 783, 1998.
22. Lederman, R.J., Mendelsohn, F.O., Anderson, R.D., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359, 2053, 2002.
23. Lazarous, D.F., Unger, E.F., Epstein, S.E., et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 36, 1239, 2000.
24. Floege, J., Hudkins, K.L., Eitner, F., et al. Localization of fibroblast growth factor-2 (basic FGF) and FGF receptor-1 in adult human kidney. Kidney Int 56, 883, 1999.
25. Floege, J., Burg, M., Hugo, C., et al. Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 9, 792, 1998.
26. Floege, J., Kriz, W., Schulze, M., et al. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 96, 2809, 1995.
27. Francki, A., Uciechowski, P., Floege, J., von der Ohe, J., Resch, K., and Radeke, H.H. Autocrine growth regulation of human glomerular mesangial cells is primarily mediated by basic fibroblast growth factor. Am J Pathol 147, 1372, 1995.
28. Cooper, L.T., Jr., Hiatt, W.R., Creager, M.A., et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 6, 235, 2001.
29. Tabata, Y., Miyao, M., Yamamoto, M., and Ikada, Y. Vascularization into a porous sponge by sustained release of basic fibroblast growth factor. J Biomater Sci Polym Ed 10, 957, 1999.
30. Tabata, Y., Hijikata, S., Muniruzzaman, M., and Ikada, Y. Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sci Polym Ed 10, 79, 1999.
31. Hashimoto, T., Koyama, H., Miyata, T., et al. Selective and sustained delivery of basic fibroblast growth factor (bFGF) for treatment of peripheral arterial disease: results of a phase I trial. Eur J Vasc Endovasc Surg 38, 71, 2009.
32. Takehara, N., Tsutsumi, Y., Tateishi, K., et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol 52, 1858, 2008.